Stocks Health care INBX
NASDAQ · Health careInhibrx Biosciences, Inc. (INBX)
It posted a net loss of $138.2M. In fiscal 2025 capital spending exceeded operating cash flow by $129.8M. At June 30, 2026 it held $133.3M in cash against $176.3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Inhibrx Biosciences, Inc.
- Net worth
- Inhibrx Biosciences, Inc. has a market value (market cap) of $1.3B at the latest share price, and shareholders' equity of -$53M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.3M (+550.0% year on year), with a net loss of $140.1M.
- Cash flow
- In fiscal 2025 operations used $129.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Inhibrx Biosciences, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Inhibrx Biosciences, Inc. does
Inhibrx Biosciences, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker INBX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.3M | -$140.1M | -$9.04 | -$129.8M |
| 2024 | $200K | $1.7B | $112.62 | -$197M |
| 2024 | $1.8M | -$241.4M | -$20.48 | -$197.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where INBX ranks in Health care
Latest SEC filings
What Inhibrx Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 28, 2026Passive stake changed SCHEDULE 13G/A
- September 28, 2026
- September 8, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026
- August 13, 2026
- August 3, 2026Passive stake (5% or more) SCHEDULE 13G
- July 16, 2026
Insider trades
What the people running Inhibrx Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $6.3M and sold $279K worth of shares in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 14, 2026 | Lappe MarkChief Executive Officer, Director | Boughtindirect | 2,470 | $207.7K |
| October 14, 2026 | Lappe MarkChief Executive Officer, Director | Boughtindirect | 2,470 | $209.9K |
| October 14, 2026 | Lappe MarkChief Executive Officer, Director | Boughtindirect | 100 | $8.6K |
| October 14, 2026 | Lappe MarkChief Executive Officer, Director | Boughtindirect | 2,449 | $205.9K |
| October 14, 2026 | Lappe MarkChief Executive Officer, Director | Boughtindirect | 2,451 | $208.3K |
| October 14, 2026 | Lappe MarkChief Executive Officer, Director | Boughtindirect | 100 | $8.6K |
| September 28, 2026 | Lappe MarkChief Executive Officer, Director | Boughtindirect | 1,500 | $148.3K |
| September 28, 2026 | Lappe MarkChief Executive Officer, Director | Boughtindirect | 3,000 | $305.1K |
Who owns INBX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Perceptive Advisors LLC13G, passive with 2 related filers | 9.99% | August 14, 2026 |
| Viking Global Investors LP13G, passive with 10 related filers | 9.3% | August 14, 2026 |
| Jon Faiz Kayyem13D, may seek influence with 1 related filers | 5.65% | June 3, 2024 |
| Schonfeld Strategic Advisors LLC13G, passive | 5.33% | August 14, 2026 |
| Mark Lappe13D, may seek influence | 5.26% | June 3, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 163 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Morgan Stanley | 1,308,051 | +44,973 |
| Perceptive Advisors LLC | 1,297,763 | -144,944 |
| Sanofi | 1,157,926 | 0 |
| Viking Global Investors LP | 1,123,929 | -313,776 |
| HighTower Advisors, LLC | 870,551 | +351 |
| Bank of America Corp | 841,141 | +808,458 |
| BlackRock, Inc. | 825,972 | +27,074 |
| Schonfeld Strategic Advisors LLC | 697,586 | +442,759 |
| State Street Corp | 640,458 | +89,613 |
| Vanguard Capital Management LLC | 492,477 | +6,055 |
| Woodline Partners LP | 400,892 | +16,459 |
| Capital Research Global Investors | 363,050 | -29,797 |
| Goldman Sachs Group Inc | 338,176 | +243,102 |
| PFM Health Sciences, LP | 308,385 | +2,954 |
| Sofinnova Investments, Inc. | 303,103 | -102,926 |
| Healthcare of Ontario Pension Plan Trust Fund | 271,700 | +101,000 |
| Parkman Healthcare Partners LLC | 256,950 | new |
| Geode Capital Management, LLC | 256,175 | +24,666 |
| First Turn Management, LLC | 164,783 | new |
| Millennium Management LLC | 147,200 | -180,660 |
Insiders
4 insiders reported holding 838,924 shares in total, about $76M at the last price.
| Holder | Shares |
|---|---|
| Kayyem Jon FaizDirector | 434,360434,360 held indirectly |
| Forsyth DouglasDirector | 227,064227,064 held indirectly |
| Lappe MarkChief Executive Officer, Director | 170,000170,000 held indirectly |
| Manhard KimberlyDirector | 7,5007,500 held indirectly |
Questions about INBX
What does Inhibrx Biosciences, Inc. do?
Inhibrx Biosciences, Inc. is a company in the Health care sector, listed on NASDAQ as INBX. Its shares trade on NASDAQ under the ticker INBX.
What is Inhibrx Biosciences, Inc.'s net worth?
Inhibrx Biosciences, Inc. has a market value (market cap) of $1.3B at the latest share price, and shareholders' equity of -$53M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Inhibrx Biosciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $138.2M.
When did Inhibrx Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from October 28, 2026.
When is Inhibrx Biosciences, Inc.'s next earnings report?
Inhibrx Biosciences, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare INBX with
Follow INBX
Get an email when Inhibrx Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Inhibrx Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.